Arhiiv

PTC Therapeutics sõlmib ülemaailmse litsentsi- ja koostöölepingu Novartisiga PTC518 Huntingtoni tõve programmi jaoks

December 2, 2024 – PTC to receive $1.0B in cash at closing –– PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones –– PTC to share profits in the U.S. and […]

Sage Therapeutics lõpetab dalzanemdor'i arendamise HD puhul

The Phase 2 DIMENSION Study did not meet its primary endpoint Dalzanemdor was generally well-tolerated; no new safety signals were observed Based on these data, the Company does not plan […]

Partnerluse jõud. Šveits ja Hiina on eeskujuks.

In this video, Professor Jean-Marc Burgunder, head of the Huntington’s Disease (HD) centre in Bern Switzerland, and Xi Cao, President of the Chinese HD Association talk about the benefits of […]

Elamisväärsed elud - uus raamat, mis toob esile HD poolt mõjutatud inimeste lugusid kogu maailmas.

PRESS RELEASE – October 25, 2024, Moscow, Idaho, USAWe are pleased to announce the launch of a new book about Huntington’s disease (HD) called, Livable Lives: Conversations with the Huntington’s […]

LoQus23 Therapeutics teatab 35 miljoni naelsterlingi suurusest rahastamisest, et arendada uut ravimit, mille eesmärk on pärssida somaatilist laienemist Huntingtoni tõve korral.

Cambridge, UK, 2 October 2024 – LoQus23 Therapeutics Ltd (“LoQus23”), a private biotechnology company investigating small molecule drugs that could stop DNA instability and slow neurodegeneration in Huntington’s Disease, myotonic dystrophy […]

MENA haruldaste haiguste kongress

HDYO kongress

FDA annab PTC518 Huntingtoni tõve programmile kiireloomulise nimetuse

PTC518 is an oral medication that reduces the production of the mutated Huntingtin protein that causes disease progression.   Programs with Fast Track designation can benefit from early interactions with the FDA, and may be […]

Prilenia's Pridopidine's Huntingtoni tõve raviks on heaks kiidetud Euroopa müügiloa läbivaatamine

Prilenia, a clinical stage biotechnology company focused on the urgent mission to develop novel therapeutics to slow the progression of neurodegenerative diseases and neurodevelopmental disorders, has filed a European Marketing […]

Kibedate otsingute kroonika: The Making of a Foundation

I belong to the third generation of a family affected by Huntington’s Disease, but it wasn’t until 2024, thanks to the tireless efforts of my second father, F. Cook, that […]